Fens Niki, Zwinderman Aeilko H, van der Schee Marc P, de Nijs Selma B, Dijkers Erica, Roldaan Albert C, Cheung David, Bel Elisabeth H, Sterk Peter J
Department of Respiratory Medicine, F5-260, Academic Medical Centre, University of Amsterdam, P.O. Box 22700, Amsterdam NL-1100 DE, The Netherlands.
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1076-82. doi: 10.1164/rccm.200906-0939OC. Epub 2009 Aug 27.
Chronic obstructive pulmonary disease (COPD) and asthma can exhibit overlapping clinical features. Exhaled air contains volatile organic compounds (VOCs) that may qualify as noninvasive biomarkers. VOC profiles can be assessed using integrative analysis by electronic nose, resulting in exhaled molecular fingerprints (breathprints).
We hypothesized that breathprints by electronic nose can discriminate patients with COPD and asthma.
Ninety subjects participated in a cross-sectional study: 30 patients with COPD (age, 61.6 +/- 9.3 years; FEV(1), 1.72 +/- 0.69 L), 20 patients with asthma (age, 35.4 +/- 15.1 years; FEV(1) 3.32 +/- 0.86 L), 20 nonsmoking control subjects (age, 56.7 +/- 9.3 years; FEV(1), 3.44 +/- 0.76 L), and 20 smoking control subjects (age, 56.1 +/- 5.9 years; FEV(1), 3.58 +/- 0.78). After 5 minutes of tidal breathing through an inspiratory VOC filter, an expiratory vital capacity was collected in a Tedlar bag and sampled by electronic nose. Breathprints were analyzed by discriminant analysis on principal component reduction resulting in cross-validated accuracy values (accuracy). Repeatability and reproducibility were assessed by measuring samples in duplicate by two devices.
Breathprints from patients with asthma were separated from patients with COPD (accuracy 96%; P < 0.001), from nonsmoking control subjects (accuracy, 95%; P < 0.001), and from smoking control subjects (accuracy, 92.5%; P < 0.001). Exhaled breath profiles of patients with COPD partially overlapped with those of asymptomatic smokers (accuracy, 66%; P = 0.006). Measurements were repeatable and reproducible.
Molecular profiling of exhaled air can distinguish patients with COPD and asthma and control subjects. Our data demonstrate a potential of electronic noses in the differential diagnosis of obstructive airway diseases and in the risk assessment in asymptomatic smokers. Clinical trial registered with www.trialregister.nl (NTR 1282).
慢性阻塞性肺疾病(COPD)和哮喘可表现出重叠的临床特征。呼出气体中含有挥发性有机化合物(VOCs),其可能作为无创生物标志物。可通过电子鼻进行综合分析来评估VOC谱,从而得到呼出分子指纹(呼吸印记)。
我们假设电子鼻的呼吸印记可区分COPD患者和哮喘患者。
90名受试者参与了一项横断面研究:30例COPD患者(年龄61.6±9.3岁;第1秒用力呼气容积[FEV(1)] 1.72±0.69 L),20例哮喘患者(年龄35.4±15.1岁;FEV(1) 3.32±0.86 L),20名非吸烟对照者(年龄56.7±9.3岁;FEV(1) 3.44±0.76 L),以及20名吸烟对照者(年龄56.1±5.9岁;FEV(1) 3.58±0.78)。通过吸气VOC过滤器进行5分钟潮式呼吸后,在Tedlar袋中收集呼气肺活量并由电子鼻采样。通过对主成分降维进行判别分析来分析呼吸印记,得到交叉验证准确度值(准确度)。通过两台设备对样本进行重复测量来评估重复性和再现性。
哮喘患者的呼吸印记与COPD患者(准确度为96%;P<0.001)、非吸烟对照者(准确度为95%;P<0.001)以及吸烟对照者(准确度为92.5%;P<0.001)的呼吸印记相区分。COPD患者的呼出气体谱与无症状吸烟者的呼出气体谱部分重叠(准确度为66%;P = 0.006)。测量具有可重复性和再现性。
呼出气体的分子谱分析可区分COPD患者、哮喘患者和对照者。我们的数据证明了电子鼻在阻塞性气道疾病鉴别诊断及无症状吸烟者风险评估中的潜力。在www.trialregister.nl注册的临床试验(NTR 1282)。